<DOC>
	<DOC>NCT00515866</DOC>
	<brief_summary>The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.</brief_summary>
	<brief_title>Study to Assess the Safety &amp; Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of pancreas Locally advanced or metastatic unresectable disease No prior anti cancer chemotherapy, radiotherapy (except palliative &gt;4 weeks prior to entry, endocrine or immunotherapy or use of other investigational agents;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Advanced pancreatic cancer</keyword>
	<keyword>Poly (ADP ribose) polymerases</keyword>
	<keyword>Advanced Solid Tumours</keyword>
</DOC>